Daiichi Sankyo Co., Ltd.

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-23 am EDT			5-day change	1st Jan Change
4,663 ^JPY	+0.65%		+2.24%	+20.43%

Apr. 19	Middle East Tensions Dent Asian Stock Markets	MT
Apr. 10	Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	MT

DAIICHI SANKYO COMPANY, LIMITED : TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy

December 20, 2013 at 02:32 am EST

MarketScreener.com By The editorial team

For Immediate Release

2013.12.20

Mitsubishi Tanabe Pharma Corporation
Daiichi Sankyo Co., Ltd.

TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy

OSAKA and TOKYO, Japan, December 20, 2013---Mitsubishi Tanabe Pharma Corporation (hereafter, Mitsubishi Tanabe Pharma; President & CEO: Michihiro Tsuchiya) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo; President & Representative Director: Joji Nakayama) announced today that Mitsubishi Tanabe Phama has received approval of a partial change in indication for TENELIA® 20mg tablets (generic name: Teneligliptin hydrobromide hydrate) for the treatment of type 2 diabetes mellitus.

Based on the approval of the partial change, the indication of TENELIA® has changed to "type 2 diabetes mellitus" based on the "Guideline for Clinical Evaluation of Oral Hypoglycemic Agents", and TENELIA® is now available for combination therapy with existing oral hypoglycemic agents, such as biganides,

Latest news about Daiichi Sankyo Co., Ltd.

Middle East Tensions Dent Asian Stock Markets	Apr. 19	MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	Apr. 10	MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication	Apr. 08	MT
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu	Apr. 08	MT
AstraZeneca: US approval extended for Enhertu	Apr. 08	CF
AstraZeneca hails neurological data for Ultomiris, Soliris	Apr. 08	AN
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval	Apr. 08	MT
Astra hails neurology data; CVS flags cyberattack	Apr. 08	AN
AstraZeneca's, Daiichi's Enhertu receives US FDA approval	Apr. 08	AN
AstraZeneca Wins US Approval for Solid Tumor Treatment	Apr. 07	MT
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors	Apr. 05	CI
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors	Apr. 05	RE
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer	Apr. 03	MT
Merck: 1st patient in raludotatug study	Apr. 03	CF
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	CI
AstraZeneca, Daiichi make US progress with licence approvals	Apr. 03	AN
FTSE 100 Ends Lower; UK Manufacturing Sector Escapes Contraction	Apr. 02	MT
AstraZeneca, Daiichi Sankyo Say US FDA Accepts Their Biologics License Application for Breast Cancer Treatment	Apr. 02	MT
AstraZeneca and Daiichi make US progress with latest licence approvals	Apr. 02	AN
AstraZeneca, Daiichi Sankyo's Jointly Developed Breast Cancer Treatment Accepted for US Regulatory Review	Apr. 02	MT
HSBC in special payout on Canada sale; Astra FDA win	Apr. 02	AN
AstraZeneca, Daiichi Sankyo Seek US FDA Approval for Breast Cancer Drug	Apr. 02	MT
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	Apr. 02	CI
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update	Mar. 22	MT
Esperion Therapeutics Gets CHMP Positive Opinion for Cholesterol Medications	Mar. 22	DJ

Chart Daiichi Sankyo Co., Ltd.

Duration

Period

More charts

Company Profile

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4,663 JPY

Average target price

5,620 JPY

Spread / Average Target

+20.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAIICHI SANKYO CO., LTD.	+20.43%	57.4B
ELI LILLY AND COMPANY	+27.04%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.33%	359B
MERCK & CO., INC.	+16.33%	322B
ABBVIE INC.	+9.72%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.84%	149B

Other Pharmaceuticals

Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Pharmaceuticals

DAIICHI SANKYO COMPANY, LIMITED : TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy

EPS Revisions